拜阿司匹林联合替格瑞洛对冠心病PCI患者心功能及MACE发生率的影响

Effect of Bayaspirin combined with ticagrelor on cardiac func-tion and MACE incidence in patients with coronary heart dis- ease undergoing PCI

目的探讨拜阿司匹林联合替格瑞洛对冠心病经皮冠状动脉介入术患者心功能及主要不良心血管事件发生率的影响.方法将82例行经皮冠状动脉介入术的冠心病患者按照随机数字表法分为两组,各41例.研究组给予拜阿司匹林联合替格瑞洛治疗,对照组给予拜阿司匹林联合氯吡格雷治疗.比较两组治疗前后心功能指标及血清炎性因子水平.随访1a,比较两组主要不良心血管事件发生率.结果治疗后两组左心室射血分数水平显著高于治疗前(P<0.05),左心室收缩末期容积及左心室舒张末期容积水平显著低于治疗前(P<0.05或0.01),研究组较对照组变化更显著(P<0.05或0.01).治疗后两组血清肿瘤坏死因子-α、超敏C反应蛋白、白细胞介素-6水平均较治疗前显著降低(P<0.01),研究组较对照组下降更显著(P<0.05或0.01).研究组主要不良心血管事件发生率显著低于对照组(P<0.05).结论拜阿司匹林联合替格瑞洛可以显著改善冠心病经皮冠状动脉介入术患者的心功能,降低炎性因子水平及主要不良心血管事件发生率.

Objective To investigate the effect of Bayaspirin com bined with ticag relor on cardiac function and MACE incidence in patients with coronary heart disease undergoing PCI.Methods 82 patients with coronary heart disease who underw ent percutaneous coronary intervention were randomly divided into two groups,41 cases in each group.The study group received Bayaspirin plus tigrelor and the control group re-ceived Bayaspirin plus clopidogrel.The cardiac function indexes and serum inflam matory factors levels of the two groups were compared before and af ter treatment.The incidence of major adverse cardiovascular events was compared between the two groups after 1 a follow-up.Results After treatment,the levels of LVEF of the two groups were significantly higher than those before treatment ( P<0.05 ).The levels of LV ESV and LVEDV were significantly lower than those before treatment ( P<0.05 or 0.01).The study group changed more significantly than the control group ( P< 0.05 or 0.01 ).Af ter treatment, serum TNF-α,hs-CRP and IL-6 levels were significantly lower than those before treatment ( P<0.01),the stud-y group decreased more significantly than the control group ( P<0.05 or 0.01).The incidence of M ACE in the study group was significantly lower than that in the control group (P<0.05).Conclusion Bayaspi-rin com bined with ticagrelor can significantly improve cardiac function,reduce inflam matory factor levels and the incidence of major adverse cardiovascular events in patients with coronary artery disease undergo-ing percutaneous coronary intervention.